Division of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California.
Cancer Prev Res (Phila). 2022 Mar 1;15(3):173-183. doi: 10.1158/1940-6207.CAPR-21-0264.
Though studies have observed inverse associations between use of analgesics (aspirin, NSAIDs, and acetaminophen) and the risk of several cancers, the potential biological mechanisms underlying these associations are unclear. We investigated the relationship between analgesic use and serum concentrations of estrogens, androgens, and their metabolites among postmenopausal women to provide insights on whether analgesic use might influence endogenous hormone levels, which could in turn influence hormone-related cancer risk. The study included 1,860 postmenopausal women from two case-control studies nested within the Women's Health Initiative Observational Study. Analgesic use was reported at study baseline. Fifteen estrogens and estrogen metabolites and 12 androgens and androgen metabolites were quantified in baseline serum by LC/MS-MS. Linear regression with inverse probability weighting, stratified by menopausal hormone therapy (MHT) use, was used to estimate adjusted geometric mean concentrations of each hormone by analgesic use. Among women not currently using MHT (n = 951), low-dose aspirin (<100 mg) use was associated with a higher serum concentration of estrone, estradiol, and 2, 4, and 16 hydroxylated metabolites. Use of regular-dose aspirin (≥100 mg), non-aspirin NSAIDs, and acetaminophen was not associated with serum concentrations of estrogens, androgens, or their metabolites. This study highlights the importance of examining aspirin use by dose and suggests that low-dose aspirin may influence endogenous estrogen concentrations.
This study explores a potential pathway by which analgesic medications such as aspirin may prevent hormone-related cancers. The findings support a positive association between low-dose aspirin use and endogenous estrogens, indicating that further elucidation of the interplay between low-dose aspirin, estrogen concentrations, and cancer risk is needed.
尽管有研究观察到使用镇痛药(阿司匹林、非甾体抗炎药和对乙酰氨基酚)与几种癌症风险之间呈反比关系,但这些关联背后的潜在生物学机制尚不清楚。我们研究了绝经后妇女使用镇痛药与血清雌激素、雄激素及其代谢物浓度之间的关系,以期了解使用镇痛药是否会影响内源性激素水平,进而影响与激素相关的癌症风险。该研究纳入了来自妇女健康倡议观察研究中嵌套的两项病例对照研究的 1860 名绝经后妇女。在研究基线时报告了镇痛药的使用情况。通过 LC/MS-MS 在基线血清中定量了 15 种雌激素和雌激素代谢物以及 12 种雄激素和雄激素代谢物。采用基于逆概率加权的线性回归,按激素替代疗法(MHT)使用情况进行分层,估计了每个激素的经镇痛药使用校正后的几何均数浓度。在未使用 MHT 的女性(n=951)中,低剂量阿司匹林(<100mg)的使用与雌酮、雌二醇和 2、4、16 羟基代谢物的血清浓度较高相关。常规剂量阿司匹林(≥100mg)、非阿司匹林 NSAIDs 和对乙酰氨基酚的使用与雌激素、雄激素或其代谢物的血清浓度无关。这项研究强调了按剂量检查阿司匹林使用的重要性,并表明低剂量阿司匹林可能会影响内源性雌激素浓度。
本研究探讨了镇痛药(如阿司匹林)预防激素相关癌症的一种潜在途径。这些发现支持低剂量阿司匹林使用与内源性雌激素之间存在正相关关系,表明需要进一步阐明低剂量阿司匹林、雌激素浓度和癌症风险之间的相互作用。